Teon Therapeutics Inc.

Teon Therapeutics Inc.

is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2017. The company focuses on discovering and developing oral, single-target small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon's mission is to restore anti-tumor immunity and suppress cancer cell proliferation by targeting immunosuppressive and cancer-promoting pathways, particularly in difficult-to-treat cancers. Teon specializes in drug discovery and development, with a pipeline of small-molecule candidates aimed at enhancing anti-cancer immunity. Their lead product, TT-702, is designed to block adenosine-mediated immune suppression and is expected to enter Phase 1b trials. The company collaborates with biopharmaceutical firms and research institutions to advance its innovative therapies, which are designed for once-daily oral administration to improve patient compliance and treatment outcomes. Teon Therapeutics is recognized for its contributions to immunotherapy solutions in oncology.